

# Structural and Functional Characterization of the Aorta in Hypertrophic Obstructive Cardiomyopathy

AM. Ibrahim<sup>1,2</sup>, N. Latif<sup>3</sup>, M. Roshdy<sup>1</sup>, P. Sarathchandra<sup>3</sup>, M. Hosny<sup>1,4</sup>, A. Elsayy<sup>1</sup>, S. Hekal<sup>1</sup>, A. Attia<sup>1</sup>, W. Elmozy<sup>1</sup>, A. Elaithy<sup>1</sup>, A. Elguindy<sup>1</sup>, A. Afifi<sup>1</sup>, Y. Aguib<sup>1,3\*</sup>, M. Yacoub<sup>1,3\*</sup>

<sup>1</sup> Aswan Heart Center, Magdi Yacoub Heart Foundation, Aswan 200, Egypt

<sup>2</sup> Department of Zoology, Faculty of Science, Cairo University, Giza 12613, Egypt.

<sup>3</sup> National Heart and Lung Institute, Imperial College London, London SW3 6LY, UK.

<sup>4</sup> Cardiology Department, Faculty of Medicine, Cairo University, Giza 11562, Egypt.

\*authors contributed equally

**Corresponding authors:** Ayman M. Ibrahim and Magdi Yacoub

E-mails: [ayman.maher@aswanheartcentre.com](mailto:ayman.maher@aswanheartcentre.com) and [m.yacoub@imperial.ac.uk](mailto:m.yacoub@imperial.ac.uk)

Address: Aswan Heart Centre, Kasr ElHagar street, Aswan, Egypt

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 1 Abstract

2 **Background and aims:** Changes in the phenotype and genotype in Hypertrophic  
3 Obstructive Cardiomyopathy (HOCM) are thought to involve the myocardium as well  
4 as extracardiac tissues. The extent and significance of extra-myocardial changes has  
5 not been adequately studied. We here describe the structural and functional changes  
6 in the ascending aorta of HOCM patients.

7 **Methods:** Changes in the aortic wall were studied in a cohort of 102 consecutive  
8 HOCM patients undergoing myectomy, and 10 normal controls. Biopsies were  
9 examined histologically, immunohistochemically and by electron microscopy. Changes  
10 in protein expression were quantified using morphometry and western blotting. Pulse  
11 wave velocity (PWV) was measured using Cardiac Magnetic Resonance (CMR), in 86  
12 HCM patients compared to 166 age-matched normal controls.

13 **Results:** In HCM, the number of medial lamellar units (MLU) was significantly  
14 decreased, associated with an increase in the interlamellar distance and a preserved  
15 thickness of the aortic wall, as compared to controls. Electron microscopy showed an  
16 altered lamellar structure with disorientation of elastin fibers from the circumferential  
17 direction. There was an altered composition and orientation of smooth muscle cells. In  
18 addition, there was a significant decrease in alpha-smooth muscle actin, smooth  
19 muscle myosin, smooth muscle 22 and integrin beta1, and a significant increase in  
20 calponin and caspase3. Fibulins 1, 2 and 5, had a reduced expression in HOCM aortic  
21 biopsies. Functionally, PWV was significantly higher in HOCM patients compared to  
22 healthy controls.

23 **Conclusion:** In HOCM patients, specific molecular and structural changes in the  
24 composition and organisation of the arterial wall have been identified. This was  
25 associated with increased stiffness of the arterial wall.

26 **Keywords:** HCM, Aortic wall, lamellae, ECM, PWV

## 1    **Translational Perspective**

2    This study sheds light for the first time on the altered lamellar organization in  
 3    the aorta of Hypertrophic Obstructive Cardiomyopathy (HOCM), in addition to  
 4    the Smooth muscle cells and Extracellular Matrix abnormalities, to explain the  
 5    increased wall stiffness associated with patients clinical phenotype. The data  
 6    provide insights on extra-myocardial targets that can have potential value for  
 7    risk stratification and personalized therapeutics for HOCM patients.

## 8    **Introduction**

9    Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder affecting  
 10    more than 1:500 in the general population <sup>1–3</sup>. HCM has always been defined  
 11    with various myocardial changes and concentrating on disease-causing  
 12    mutations related to sarcomeric genes <sup>4–6</sup>. However, recent evidence has  
 13    shown that HCM is heterogenous both at genotype and phenotype levels and  
 14    involves many pathways and extra-myocardial tissues, such as the aorta <sup>7,8</sup>.

15    Changes in the aortic stiffness have been reported in HCM <sup>9,10</sup> and correlated  
 16    to exercise capacity <sup>11</sup>. To date, the structural changes responsible for  
 17    abnormalities in the aortic wall have not been studied. The wall of the aorta is  
 18    highly elastic and dynamic which facilitates its function and response to the  
 19    hemodynamic environment <sup>12–14</sup>. One of the major players that determine the  
 20    arterial wall stiffness, and the physical properties of the aorta, is the medial  
 21    elastic lamellar number and composition, which was first described by Glagov  
 22    and colleagues <sup>15–17</sup>. This observation has since been the subject of many  
 23    studies focusing on the medial lamellar unit (MLU) organization in physiological  
 24    and pathological conditions <sup>18,19</sup>, which sometimes yielded contradictory results

1 due to the lack of adequate imaging techniques that can determine the 3D  
2 structure of the MLU. A recent 3D modeling and imaging of MLU clarified their  
3 exact composition and the functional interaction between the constituting  
4 elements.<sup>19</sup> The interlamellar space contains smooth muscle cells (SMCs) and  
5 different extracellular matrix (ECM) components, which play a critical role in  
6 determining the physical properties of the aortic wall, including stiffness<sup>20–23</sup>.  
7 Elastin and collagen are the major components of the aortic wall ECM,  
8 however, other matrix proteins such as fibrillin, fibulins (FBLNs), and matrix  
9 metalloproteinases also play an important function in the aortic wall structure  
10<sup>21</sup>.

11 We here study in detail the number of elastic lamellae, and the width and  
12 composition of the interlamellar space, particularly in relation to the changes in  
13 ECM components as well as SMCs.

## 14 **Methods**

### 15 **Patients samples**

16 In all, 268 subjects were clinically examined (102 HCM and 166 controls [from  
17 the ECCO-GEN study<sup>24</sup>](**Table 1** and **Supplementary data**). Written informed  
18 consent was obtained from HCM patients and healthy subjects prior to their  
19 inclusion in the study [(20130405MYFAHC\_CM\_20130330) and  
20 (20151125MYFAHC\_Hvol\_20161027), respectively]. Control aortic biopsies  
21 were acquired from the Magdi Yacoub Institute UK, upon a material transfer  
22 agreement [Royal Brompton hospital ethics review board / Brompton and  
23 Harefield trust ethics committee (REC approval 10/H0724/18)]. The study is  
24 abiding by all the standards of the Declaration of Helsinki.

**Table 1: Clinical characteristics of Hypertrophic Cardiomyopathy (HCM) and Healthy volunteers [HVol] cohorts.**

Clinical Parameters	HCM (n = 102)	Hvol (n=166)
Gender, Male n (%)	74 (72)	93 (56)
Age, years	39.4 ± 14.3	32.8 (25–36)
Body surface area BSA. m <sup>2</sup>	1.9 (1.71–2.1)	1.8 (1.7–2.0)
Body mass index	28.7 ± 6.2	26.4 (22.8–29.2)
Dyspnea n (%) New York Heart Association (NYHA) class	95 (93) Class I (n = 4) Class II (n = 31) Class III (n = 51) Class IV (n = 9)	0(0)
Angina n (%)	51 (0.5)	0(0)
Syncope	24(23)	0(0)
Max Septal wall thickness (cm)	2.4 (2– 2.8) *	NA
LVOTO resting gradient (mmHg)	103 (80–128)	NA
Left ventricular mass by CMR (gm)	204.5 (163.8–298.5) *	85.19 (62–106)
Left ventricular end systolic volume by CMR (ml)	19 (14–27) <sup>α</sup>	51.9 (39–61)
Left ventricular end diastolic volume by CMR (ml)	78 (67–93) <sup>α</sup>	134.58 (113–154)
Ejection Fraction% by CMR	74.9 ± 8.21 <sup>α</sup>	63.4 (59–67)
Diastolic dysfunction n(%) Diastolic dysfunction Grade	102(100) Class 1 (n = 93) Class 2 (n = 7) Class 3 (n = 2)	0(0)
Cardiac Troponin I (ng/mL)	0.014 (0.009–0.03) <sup>¥</sup>	0.003 (0.0001–0.002) <sup>∞</sup>

\*The data are available for 91 patients only, <sup>α</sup> the data are available for 92 patients only, <sup>¥</sup> the data are available for 75 patients only, <sup>∞</sup> the data are available for 158 patients only, <sup>Σ</sup> the data are available for 86 patients only. Data are presented as mean ± SD for normally distributed continuous variables, as median and interquartile range for non-normally distributed continuous variables, and as percentages (%) for categorical variables.

## Tissue processing and histological staining

Thoracic aortic biopsies were collected, processed and prepared for staining as described before <sup>25</sup>. Briefly, for fibrous collagen staining, slides were incubated in picrosirius red stain (Abcam) for 1 hr and washed in 0.5% acetic acid for differentiation. Sections were dehydrated with increasing concentrations of ethanol, cleared with two changes of xylene (Sigma) and finally mounted with

1 DPX (Sigma). Slides were scanned and analyzed with a slide scanner (Zeiss-  
2 Axioscan).

### 3 **Immunohistochemistry and immunofluorescence**

4 Section preparation was performed as described before <sup>25,26</sup>. All antibodies  
5 were diluted using blocking solution; α-SMA 1:300 (Thermo Scientific™, # MS-  
6 113-P, SMM 1:200 (Abcam, ab 133567), SM22 1:200 (abcam, ab14106)  
7 calponin 1:200 (Dako, M3556), ITGβ1 1:150 (Abcam, #ab52971), Caspase3  
8 1:50 (Abcam, #ab13847) FBLN2 1:200 (Thermo Scientific™, #PA5-21640),  
9 FBLN1 1:200 (Thermo Scientific™, #MA5-24598) and FBLN5 1:200 (Thermo  
10 Scientific™, #MA5-15395). Sections were incubated for 1 hr with HRP-goat  
11 secondary antibody (Dako) and washed thrice prior to staining with DAB plus  
12 Chromogen (Dako) for 1 min. For fluorescence reactions, washed sections  
13 were incubated with secondary antibodies conjugated with fluorophores, (Goat  
14 Anti-Mouse IgG H&L Alexa Fluor® 594) (abcam, ab150116) and (Goat Anti-  
15 Rabbit IgG H&L Alexa Fluor® 488) (Abcam, #ab150077) at a 1:500 dilution,  
16 incubated in the dark for 1 hr at RT, and then mounted with DAPI-containing  
17 mounting media (Invitrogen™, Carlsbad, CA, USA, #P36962). The number of  
18 lamellae and interlamellar distance were measured using Glagov's  
19 methodology <sup>16,27</sup>.

### 20 **Protein isolation and immunoblotting**

21 Tissue biopsies were lysed and prepared for separation as described before  
22 <sup>25,28</sup>. Briefly, 5 µg of protein per sample was separated and then transferred  
23 from the SDS polyacrylamide gel onto Whatman® Protran® Nitrocellulose  
24 Transfer Membrane (0.2 µm) (Sigma) using a Biorad transfer module, protein

1 transfer buffer (1X NuPage transfer buffer, 10% methanol in dH<sub>2</sub>O). The  
2 membrane was incubated for 30 min at RT in 5% Marvel Original dried skimmed  
3 milk blocking solution (in 1X PBS Tween-20 wash buffer). The membrane was  
4 then incubated for 2 hrs at RT with primary antibody (GAPDH (Cell Signaling,  
5 2118S) at 1:500, FBLN2 at 1:1000, FBLN5 at 1:100 and FBLN1 at 1:1000),  
6 washed thrice for 15 min, incubated for 1 hr at RT with horseradish peroxidase  
7 (HRP)-labelled secondary antibody (Life Technologies) and washed thrice for  
8 15 min. Reaction with HRP was carried out using ECL Western blotting  
9 detection reagents (Life Technologies) and the signal was detected using an  
10 Amersham Imager 600.

# 11 **Electron microscopy**

12 2 mm<sup>2</sup> samples were processed as described before <sup>29</sup>. Specimens were  
13 embedded in rubber molds, polymerised in the oven at 60°C. Ultra-thin sections  
14 (100nm) were collected on coated grids, post-stained with 2% aqueous Uranyl  
15 acetate and Reynolds lead citrate and viewed using JEOL 1200 transmission  
16 electron microscope. Digital micrographs were taken using a Gatan digital  
17 camera.

# 18 **Pulse wave velocity**

19 Cardiac magnetic resonance (CMR) was performed with a 1.5 T MRI machine  
20 (Magnetom Aera - Siemens Healthineers, Erlanger, Germany). Pulse wave  
21 velocity (PWV) was calculated using Segment software (Medviso AB, Lund,  
22 Sweden), as per the formula; **PWV =  $\Delta D / \Delta T$  (m/s)**, where  $\Delta D$  was the aortic  
23 path length between the mid-aortic valve and mid-descending aorta, and  $\Delta T$

1 was the time delay between the arrival of the foot of the pulse wave at these  
2 levels. (**Supplementary methods and Supplementary Figure 1 and 2**).

## 3 **Results**

### 4 **1. The number and organization of MLU in HOCM aortic walls**

5 The interlamellar distance was significantly increased in HCM aortic walls when  
6 compared to controls, which was measured between two adjacent elastin fibres  
7 or two adjacent SMCs ( $\alpha$ -SMA+/ITG $\beta$ 1+) in the circumferential direction of the  
8 fibres. Additionally, the number of lamellae was significantly reduced in HCM-  
9 aortic walls. However, the overall thickness of the aortic wall remained  
10 unchanged in HOCM (**Figure 1B and 1C**).

11 Electron microscopy analysis of control aortic walls showed parallel  
12 circumferential organisation of lamellae and SMCs, with tightly packed  
13 interlamellar collagen in wave like formation (**Figure 1D- a, b and c**). Elastin  
14 fibers were thick, continuous lamellar sheets, with interlamellar elastin fibers  
15 and radial rods <sup>19</sup>. At lower magnification, the HCM walls showed  
16 disorganisation of the lamellar unit associated with disorientation and/or  
17 fragmentation of a group of elastin sheets from the normal circumferential  
18 direction [(**Figure 1D- a'**, red arrows) and (**Figure 1D- b'** asterix), respectively].  
19 A moth-eaten appearance was also observed in a group of elastin sheets  
20 (**Figure 1D- b' and c'**). The lamellar unit in HCM was sparsely packed at  
21 regions with ECM components compared to controls, with unoccupied spaces  
22 and areas of randomly orientated collagen (**Figure 1D- b'- c'**).

### 23 **2. Interlamellar space composition [SMCs and ECM]**


#### 24 **2.1. SMCs characteristics in HCM aorta**



1 We next investigated the expression of markers pertaining to SMCs, the cell  
2 population occupying the MLU <sup>21</sup>. Immunohistochemical analyses showed a  
3 significant reduction in the expression of alpha-smooth muscle actin ( $\alpha$ -SMA),  
4 Smooth muscle myosin (SMM), calponin, smooth muscle 22 (SM22), and  
5 integrin beta-1 (ITG $\beta$ 1), and a significant increase calponin expression in HCM-  
6 aortic walls compared to controls (**Figure 2A and supplementary Figure 3**).

7 To test whether the reduction in SMCs cells markers was associated with a  
8 depletion and/or apoptosis of SMCs, we assessed the expression of Caspase  
9 3, as an apoptosis marker <sup>28</sup>, which showed a significantly increased expression  
10 in HCM-aortic walls compared to controls (**Figure 2A**). Electron microscopy  
11 imaging showed that SMCs in HCM samples contained fat globules, vacuoles,  
12 condensed nuclei, and irregular cell outlines, which is indicative of necrotic  
13 changes compared to control SMCs. Nonetheless, nuclei of SMCs in HCM  
14 appeared to remain intact (**Figure 3**).

15  
16  
17  
18  
19  
20  
21



**Figure 1: Lamellar Organization in HCM aortic wall.** **A:** Schematic diagram shows the medial elastic lamella organization in the aortic wall [adapted from El-Hamamsy and Yacoub, 2009, and O'Connell et al., 2008]. **EL:** elastin, **ILE:** interlamellar elastin, **EL-s:** elastin spurts, **COL:** collagen, **SMC:** smooth muscle cells, **ECM:** Extracellular Matrix, **V:** Vacuole and **F:** Fat globules. **B:** Confocal Microscopy shows the altered lamellar organization in HCM aortic walls, exhibited in the expression of SMA (green)

in contrast to elastin fibres (maron). White arrows point to the interlamellar distance. **C:** Quantification of wall thickness, number of lamellae and the interlamellar distance in HCM (n=12) vs controls (n=3). **D:** Electron micrographs of control (a, b and c) (n=3) and HCM (a', b' and c') (n=14) aortic walls. Asterix refers to radial elastin fragmentation a and a' (magnification 5K, bar=5 µm), b and b' (magnification 12K, bar=2µm), c and c' (magnification 40K bar= 0.5µm).


## 2.2. ECM changes in HCM aorta – Collagen and Fibulins

Histopathological characterization of fibrous collagens in aortic wall tissues collected from HCM patients (n=102), showed a disorganization of collagen fibres compared to controls (n=10) (**Figure 4A**). Electron microscopy imaging of control collagen in transverse sections showed a minor variability in fibres diameter, however HCM samples showed a higher variability in collagen diameter and more loose fibres packing (**Figure 4B- a and b**). Similarly, longitudinal collagen fibres in control samples showed a minor variability in fibres thickness, whereas HCM samples had a group of thicker collagen strands with evident unravelling (**Figure 4B- c and d**, red arrow).


In control aortic walls, ECM proteins, FBLN1, 2 and 5, were expressed in the elastin lamina in addition to the tunica media layer with a similar pattern to collagen and elastin fibres. In HCM-aortic walls, FBLN1 and FBLN2 expression was reduced, particularly in the tunica media, while FBLN5 was reduced across all wall layers, compared to controls (**Figure 5A**). Immunoblotting analysis confirmed the reduced expression of the three FBLNs in HCM-aortic lysates (**Figure 5B and 5C**).



1




**Figure 2: Expression of SMCs markers in HCM aortic wall.** Immunohistochemical staining of  $\alpha$ -SMA, SMM, SM22, Calponin, ITG $\beta$ 1 and caspase3 in HCM-aortic biopsies (n=102) compared to controls (n=10). Scale bars are 200 $\mu$ m and 50 $\mu$ m. Bar graphs show a significant decrease of  $\alpha$ -SMA, SMM, SM22 and ITGB1, and a significant increase of calponin and caspase 3, in HCM-aortic biopsies compared to controls.




**Figure 3: SMCs abnormalities in HCM aortic wall.** Electron micrographs of control (n=3) and HCM (n=14) aortic walls, showing the altered structure in SMCs in HCM walls. F: fat globules and V: vacuoles





**Figure 4: Collagen abnormalities in HCM aortic wall. A:** Picrosirius red staining in HCM aortic biopsies (n=102) compared to controls (n=10). Scale bars are 50μm. **B:** Electron micrographs of control (a and b) (n=3) and HCM (c and d) (n=14) aortic walls. Scale bar are 0.2μm. LS: longitudinal section. TS: Transverse section.



**Figure 5: ECM abnormalities in HCM aortic wall. A:** Immunohistochemical staining of FBLNs 1, 2 and 5 in HCM-aortic walls (n=102) compared to control walls (n=10). Scale bars are 200µm and 50µm. **B:** Immunoblot shows the reduction of total protein expression for FBLNs 1, 2 and 5 in HCM-aortic walls (n=6) compared to control walls (n=2). **C:** Quantification of FBLNs 1, 2 and 5 in HCM-aortic walls (n=6) compared to control walls (n=2).

# 1 Discussion

2 This study shows significant changes in the medial lamellar unit (MLU) of the  
3 aortic wall in HOCM patients, associated with increased wall stiffness. Recent  
4 evidence has shown that HCM is not entirely due to abnormalities in the  
5 sarcomere <sup>2,3,7</sup>. This notion has been supported by genome wide association  
6 studies (GWAS), which showed that HCM is linked to changes in genes  
7 involving many pathways in addition to the well-known variations in the  
8 sarcomeric genes <sup>7</sup>.

9 One of the extracardiac manifestations of HCM is the altered stiffness of the  
10 aortic wall <sup>9,30–32</sup>, and the systemic increase of pro-fibrotic markers <sup>33,34</sup>. Aortic  
11 stiffness increases with age and is known to be an important prognostic  
12 indicator in patients with hypertension, atherosclerosis, and other diseases  
13 <sup>31,32,35</sup>. In addition, aortic stiffness has recently been shown to correlate to  
14 exercise capacity in HCM patients <sup>11</sup>. The current study confirms the increased  
15 stiffness of the aortic wall of HOCM patients, when compared to age-matched  
16 controls. To date, there have been no studies addressing the structural changes  
17 in the aortic wall of HOCM patients.

## 18 ***Aortic Medial Lamellar Unit***

19 The lamellar unit of the aorta represents the active core that plays a major part  
20 in determining the physical characteristics of the aortic wall <sup>15,18</sup>. It was originally  
21 identified by Glagov and his colleagues, and has since been validated by many  
22 studies, that the number of the lamellae is related to the dimensions, tension,  
23 and pressure of the arteries <sup>15–17,27</sup>. Recently, an advanced 3D modeling and  
24 imaging of the MLU showed two dense layers of elastin constituting the



1 boundaries of the interlamellar space. The latter contains SMCs, oriented in a  
2 specific manner, as well as collagen fibres and other components of the ECM  
3 <sup>19</sup>. Our study documents for the first time a decrease in the number of elastic  
4 lamellae and an increase in the interlamellar distance and composition. This  
5 could influence the elasticity of the arterial wall and increase its stiffness.

6 Electron microscopy and histological examination showed fragmentation in  
7 elastin sheets in HCM aortic walls. Elastin fibres confer compliance and recoil  
8 capacity to the aorta in response to mechanical stimuli <sup>13,36</sup>. Elastin  
9 fragmentation is frequently observed in many aortopathies and has been shown  
10 to stimulate SMCs turnover <sup>23</sup>, which further agrees with our analysis that  
11 identified a significant reduction in the surface and contractile markers of SMCs.

## 12 ***The interlamellar space in HOCM***

13 Apart from being wider in HOCM, the composition of the interlamellar space is  
14 altered. This is exemplified in the SMCs which showed changes in the  
15 orientation, shape, and size. These changes could possibly contribute to the  
16 increased stiffness by altering the vessel tone <sup>37,38</sup>.

17 Our findings suggest that SMCs function could be further influenced by the  
18 reduction of ITGβ1 expression. ITGβ1 is a key signaling and mechano-  
19 transduction receptor of SMCs <sup>39</sup>. We further show a significant reduction in the  
20 SMC contractile proteins which suggests the dedifferentiation of SMCs to a  
21 migratory and proliferative phenotype and/or activation of apoptosis <sup>40–42</sup>. This  
22 agrees with the increased expression of caspase3 in HCM aortic walls, an  
23 observation that has been reported in many aortopathies, particularly aortic

1 aneurysm <sup>43,44</sup>. The significance and clinical relevance of these changes  
2 requires further investigation.

3 This study also identified changes in the interlamellar space, represented in  
4 collagen and ECM proteins (FBLNs). Physiologically, collagen fibres,  
5 particularly fibrous collagens I and III, provide tensile strength and overall  
6 rigidity to the aorta <sup>45,46</sup>. Our data showed disorganized collagen fibres in HOCM  
7 aortas, which can further contribute to wall stiffness. FBLNs expression was  
8 reduced in HOCM aortic walls, particularly in the tunica intima and tunica media,  
9 suggesting their contribution to the lamellar unit's conformation and function.  
10 This was associated with a reduction in the basement membrane protein,  
11 Collage IV (**Supplementary Figure 4**), which requires FBLN2 for proper  
12 assembly <sup>47</sup>. FBLNs are a family of glycoproteins that have roles in ECM  
13 remodeling, tropoelastin maturation and collagen fibre assembly <sup>48–50</sup>. A notion  
14 suggesting their relevance to the altered MLU.

15 Structural and functional data presented in this study highlight the importance  
16 of further unravelling the composition and role of the ECM and SMCs in the  
17 human aorta in both physiological and pathological conditions, as it relates to  
18 HOCM.

19 The limitation of this study is the fact that all studied patients had obstruction  
20 which could have influenced the results, however, the aortic biopsies were high  
21 up in the ascending aorta and it's very unlikely to have been influenced by the  
22 disturbed pattern of blood flow in the aortic root.

23 In conclusion, these findings can be of special relevance to the management of  
24 HOCM by identifying high-risk patients. In addition, it could provide new  
25 therapeutic targets such as in the VANISH trial, which used Angiotensin-II

1    receptor blocker-Valsartan that could be explained, at least in part, by the effect  
2    of the drug on the arterial wall <sup>51</sup>.

### 3    **Funding**

4    This study was supported by the Science and Technology Development Fund  
5    (STDF) government grant (Egypt), **Leducq** Foundation (11 CVD-01) and  
6    Aswan Heart Centre (Magdi Yacoub Heart Foundation). The views expressed  
7    in this work are those of the authors and not necessarily those of the funders.

### 8    **Conflict of interest**

9    The authors declare no conflict of interest.

### 10    **Data availability statement**

11    All underlying data are available in the article and in its online supplementary  
12    materials.

### 13    **Acknowledgement**

14    The authors would like to thank Dr. Mona Allouba, Ms. Hadir Khedr, and Mr.  
15    Mohamed Elkhateb for their major contribution in acquiring the clinical data for  
16    control healthy cohort.

17

### 18    **References**

- 19    1.    Marian AJ. Update on hypertrophic cardiomyopathy. *Tex Heart Inst J* 2010;**37**:322–  
20    323.
- 21    2.    Elliott P. Hypertrophic cardiomyopathy lifelong disease requiring lifelong treatment.  
22    *Circulation* 2018;**138**:1399–1401.

- 1 3. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of  
2 hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2015;**65**:1249–1254.
- 3 4. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC,  
4 Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F,  
5 Seidman CE, Sajeew G, Signorovitch J, Green EM, Olivotto I. Genotype and Lifetime  
6 Burden of Disease in Hypertrophic Cardiomyopathy. *Circulation* 2018;**138**:1387–1398.
- 7 5. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis,  
8 Clinical Manifestations, Diagnosis, and Therapy. *Circ Res* 2017;**121**:749.
- 9 6. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Developmental origins of hypertrophic  
10 cardiomyopathy phenotypes: A unifying hypothesis. *Nature Reviews Cardiology*.
- 11 7. Chou C, Chin MT. Pathogenic Mechanisms of Hypertrophic Cardiomyopathy beyond  
12 Sarcomere Dysfunction. *Int J Mol Sci* 2021;**22**.
- 13 8. Maron BJ, Maron MS, Maron BA, Loscalzo J. Moving Beyond the Sarcomere to  
14 Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the  
15 Week. *J Am Coll Cardiol* 2019;**73**:1978–1986.
- 16 9. O'Rourke MF, Weber T, Adji A. Aortic Stiffness in Hypertrophic Cardiomyopathy. *J Am*  
17 *Coll Cardiol* 2010;**55**:504–505.
- 18 10. Boonyasirinant T, Rajiah P, Setser RM, Lieber ML, Lever HM, Desai MY, Flamm SD.  
19 Aortic stiffness is increased in hypertrophic cardiomyopathy with myocardial fibrosis:  
20 novel insights in vascular function from magnetic resonance imaging. *J Am Coll*  
21 *Cardiol* 2009;**54**:255–262.
- 22 11. Austin BA, Popovic ZB, Kwon DH, Thamilarasan M, Boonyasirinant T, Flamm SD, Lever  
23 HM, Desai MY. Aortic stiffness independently predicts exercise capacity in  
24 hypertrophic cardiomyopathy: a multimodality imaging study. *Heart* 2010;**96**:1303–  
25 1310.
- 26 12. Belz GG. Elastic properties and Windkessel function of the human aorta.  
27 *Cardiovascular Drugs and Therapy* 1995 9:1 1995;**9**:73–83.
- 28 13. Akhtar R, Sherratt MJ, Cruickshank JK, Derby B. Characterizing the elastic properties  
29 of tissues. *Materials Today* 2011;**14**:96–105.
- 30 14. Lin CJ, Staiculescu MC, Hawes JZ, Cocciolone AJ, Hunkins BM, Roth RA, Lin CY,  
31 Mecham RP, Wagenseil JE. Heterogeneous Cellular Contributions to Elastic Laminae  
32 Formation in Arterial Wall Development. *Circ Res* 2019;**125**:1006–1018.
- 33 15. Wolinsky H, Glagov S. A Lamellar Unit of Aortic Medial Structure and Function in  
34 Mammals. *Circ Res* 1967;**20**:99–111.
- 35 16. Glagov S, Ko C, Bassiouny HS, Zarins CK. Principles of Vascular Remodeling. *Pan*  
36 *Vascular Medicine* 2002:232–241.
- 37 17. Zatina MA, Zarins CK, Gewertz BL, Glagov S. Role of medial lamellar architecture in  
38 the pathogenesis of aortic aneurysms. *J Vasc Surg* 1984;**1**:442–448.

- 1 18. Taghizadeh H, Tafazzoli-Shadpour M. Characterization of mechanical properties of  
2 lamellar structure of the aortic wall: Effect of aging. *J Mech Behav Biomed Mater*  
3 2017;**65**:20–28.
- 4 19. O’Connell MK, Murthy S, Phan S, Xu C, Buchanan JA, Spilker R, Dalman RL, Zarins CK,  
5 Denk W, Taylor CA. The Three-Dimensional Micro- and Nanostructure of the Aortic  
6 Medial Lamellar Unit Measured Using 3D Confocal & Electron Microscopy Imaging.  
7 *Matrix Biol* 2008;**27**:171.
- 8 20. Qasem A, Avolio A. Determination of aortic pulse wave velocity from waveform  
9 decomposition of the central aortic pressure pulse. *Hypertension* 2008;**51**:188–195.
- 10 21. El-Hamamsy I, Yacoub MH. Cellular and molecular mechanisms of thoracic aortic  
11 aneurysms. *Nat Rev Cardiol* 2009;**6**:771–786.
- 12 22. Phillippi JA, Green BR, Eskay MA, Kotlarczyk MP, Hill MR, Robertson AM, Watkins SC,  
13 Vorp DA, Gleason TG. Mechanism of aortic medial matrix remodeling is distinct in  
14 patients with bicuspid aortic valve Evolving Technology/Basic Science Phillippi et al  
15 ET/BS. 2014.
- 16 23. Jana S, Hu M, Shen M, Kassiri Z. Extracellular matrix, regional heterogeneity of the  
17 aorta, and aortic aneurysm. *Experimental & Molecular Medicine* 2019 **51**:12  
18 2019;**51**:1–15.
- 19 24. Aguib Y, Allouba M, Afify A, Halawa S, El-Khatib M, Sous M, Galal A, Abdelrahman E,  
20 Shehata N, Sawy A El, Elmaghawry M, Anwer S, Kamel O, Mozy W El, Khedr H,  
21 Kharabish A, Thabet N, Theotokis PI, Buchan R, Govind R, Whiffin N, Walsh R, Aguib  
22 H, Elguindy A, O’Regan DP, Cook SA, Barton PJ, Ware JS, Yacoub M. The Egyptian  
23 Collaborative Cardiac Genomics (ECCO-GEN) Project: defining a healthy volunteer  
24 cohort. *npj Genomic Medicine* 2020 **5**:1 2020;**5**:1–8.
- 25 25. Ibrahim AM, Roshdy M, Elshorbagy S, Hosny M, Halawa S, Yehia D, Elfawy HA,  
26 Eldessouki A, Mohamed F, Ellithy A, Abdelfattah M, Elsayy A, Elkhatab M, Allouba M,  
27 Elguindy A, Aguib Y, Yacoub M. An Investigation of Fibulin-2 in Hypertrophic  
28 Cardiomyopathy. *Int J Mol Sci* 2020;**21**:1–14.
- 29 26. Kindi HN Al, Shehata M, Ibrahim AM, Roshdy M, Simry W, Aguib Y, Yacoub MH. Cor  
30 Triatriatum sinister (Divided Left Atrium): histopathological features and clinical  
31 management. *Ann Thorac Surg* 2020.
- 32 27. Xu C, Zarins CK, Glagov S. Aneurysmal and occlusive atherosclerosis of the human  
33 abdominal aorta. *J Vasc Surg* 2001;**33**:91–96.
- 34 28. Kindi HN Al, Ibrahim AM, Roshdy M, Abdelghany BS, Yehia D, Masoud AN, Simry W,  
35 Aguib Y, Yacoub MH. Clinical, cellular, and molecular characterisation of cardiac  
36 rhabdomyoma in tuberous sclerosis. *Cardiol Young* 2021;**31**:1297–1305.
- 37 29. Tseng Y-T, Grace NF, Aguib H, Sarathchandra P, McCormack A, Ebeid A, Shehata N,  
38 Nagy M, El-Nashar H, Yacoub MH, Chester A, Latif N. Biocompatibility and Application  
39 of Carbon Fibers in Heart Valve Tissue Engineering. *Front Cardiovasc Med* 2021;**8**.
- 40 30. Angoff R, Mosarla RC, Tsao CW. Aortic Stiffness: Epidemiology, Risk Factors, and  
41 Relevant Biomarkers. *Front Cardiovasc Med* 2021;**8**.

- 1 31. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness.  
2 *Hypertension* 2005;**45**:1050–1055.
- 3 32. Saeed S, Saeed N, Grigoryan K, Chowienczyk P, Chambers JB, Rajani R. Determinants  
4 and clinical significance of aortic stiffness in patients with moderate or severe aortic  
5 stenosis. *Int J Cardiol* 2020;**315**:99–104.
- 6 33. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC,  
7 Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F,  
8 Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I. Genotype and Lifetime  
9 Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric  
10 Human Cardiomyopathy Registry (SHaRe). *Circulation* 2018;**138**:1387–1398.
- 11 34. Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R,  
12 González A, Colan SD, Seidman JG, Díez J, Seidman CE. Myocardial Fibrosis as an Early  
13 Manifestation of Hypertrophic Cardiomyopathy A bs tr ac t. *N Engl J Med*  
14 2010;**363**:552–563.
- 15 35. McNulty M, Mahmud A, Spiers P, Feely J. Collagen type-I degradation is related to  
16 arterial stiffness in hypertensive and normotensive subjects. *J Hum Hypertens*  
17 2006;**20**:867–873.
- 18 36. Yanagisawa H, Wagenseil J. Elastic fibers and biomechanics of the aorta: Insights from  
19 mouse studies. *Matrix Biol* 2020;**85–86**:160–172.
- 20 37. Durgin BG, Straub AC. Redox control of vascular smooth muscle cell function and  
21 plasticity. *Laboratory Investigation* 2018;**98**:1254–1262.
- 22 38. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis.  
23 *Cardiovasc Res* 2012;**95**:156–164.
- 24 39. Humphrey JD, Schwartz MA, Tellides G, Milewicz DM. Role of Mechanotransduction  
25 in Vascular Biology. *Circ Res* 2015;**116**:1448–1461.
- 26 40. Latif N, Sarathchandra P, McCormack A, Yacoub MH, Chester AH. Atypical Expression  
27 of Smooth Muscle Markers and Co-activators and Their Regulation in Rheumatic  
28 Aortic and Calcified Bicuspid Valves. *Front Cardiovasc Med* 2022;**9**:587.
- 29 41. Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth  
30 muscle cell fate and plasticity in atherosclerosis. *Cardiovasc Res* 2018;**114**:540–550.
- 31 42. Beamish JA, He P, Kottke-Marchant K, Marchant RE. Molecular Regulation of  
32 Contractile Smooth Muscle Cell Phenotype: Implications for Vascular Tissue  
33 Engineering. *Tissue Eng Part B Rev* 2010;**16**:467.
- 34 43. Rowe VL, Stevens SL, Reddick TT, Freeman MB, Donnell R, Carroll RC, Goldman MH.  
35 Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human  
36 aortas. *J Vasc Surg* 2000;**31**:567–576.
- 37 44. Thompson RW, Liao S, Curci JA. Vascular smooth muscle cell apoptosis in abdominal  
38 aortic aneurysms. *Coron Artery Dis* 1997;**8**:623–631.

- 1 45. Pichamuthu JE, Phillippi JA, Cleary DA, Chew DW, Hempel J, Vorp DA, Gleason TG.  
2 Differential tensile strength and collagen composition in ascending aortic aneurysms  
3 by aortic valve phenotype. *Ann Thorac Surg* 2013;**96**:2147–2154.
- 4 46. Rest M Van Der, Garrone R. Collagen family of proteins. *The FASEB Journal*  
5 1991;**5**:2814–2823.
- 6 47. Ibrahim AM, Sabet S, El-Ghor AA, Kamel N, Anis SE, Morris JS, Stein T. Fibulin-2 is  
7 required for basement membrane integrity of mammary epithelium. *Scientific*  
8 *Reports* 2018 **8**:1 2018;**8**:1–14.
- 9 48. Timpl R, Sasaki T, Kostka G, Chu M-L. Fibulins: a versatile family of extracellular matrix  
10 proteins. *Nat Rev Mol Cell Biol* 2003;**4**:479–489.
- 11 49. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: Physiological and  
12 disease perspectives. *EMBO Rep* 2003;**4**:1127–1131.
- 13 50. Olijnyk D, Ibrahim AM, Ferrier RK, Tsuda T, Chu ML, Gusterson BA, Stein T, Morris JS.  
14 Fibulin-2 is involved in early extracellular matrix development of the outgrowing  
15 mouse mammary epithelium. *Cell Mol Life Sci* 2014;**71**:3811–3828.
- 16 51. Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD,  
17 Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens AT,  
18 Bundgaard H, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Vargas  
19 JD, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, Krieger JE, Sacilotto L,  
20 Arteaga E, Antunes MO, Hall EK, Choudhury L, Pahl E, Lin KY, Lewis GD, Desai AS,  
21 Burns KM, McMurray JJV, MacRae CA, Solomon SD, Orav EJ, Braunwald E. Valsartan  
22 in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. *Nat Med*  
23 2021;**27**:1818–1824.

